Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Thomas Fremming Dejgaard, Christian Seerup Frandsen, Jens Juul Holst & Sten Madsbad. (2016) Liraglutide for treating type 1 diabetes. Expert Opinion on Biological Therapy 16:4, pages 579-590.
Read now
Read now
Eva Winning Iepsen, Signe Sørensen Torekov & Jens Juul Holst. (2015) Liraglutide for Type 2 diabetes and obesity: a 2015 update. Expert Review of Cardiovascular Therapy 13:7, pages 753-767.
Read now
Read now
Manfredi Rizzo, Dragana Nikolic, Maciej Banach, Rosaria Vincenza Giglio, Angelo Maria Patti, Vittoria Di Bartolo, Annamaria Tamburello, Antonella Zabbara, Giuseppina Pecoraro, Giuseppe Montalto & Ali A Rizvi. (2013) The effects of liraglutide on glucose, inflammatorymarkersandlipoprotein metabolism: current knowledge and future perspective. Clinical Lipidology 8:2, pages 173-181.
Read now
Read now
Asger Lund, Filip K Knop & Tina Vilsbøll. (2011) Emerging GLP-1 receptor agonists. Expert Opinion on Emerging Drugs 16:4, pages 607-618.
Read now
Read now
Articles from other publishers (17)
Jidong Fang, Patti Miller & Patricia S. Grigson. (2023) Sleep is increased by liraglutide, a glucagon-like peptide-1 receptor agonist, in rats. Brain Research Bulletin 192, pages 142-155.
Crossref
Crossref
Caroline Veyder-Malberg, Dieter Furthner, Christopher Dalus, Katharina Maruszczak, Anna-Maria Schneider & Daniel Weghuber. (2020) GLP-1-Analoga in der Therapie des Typ-2-Diabetes bei JugendlichenGLP-1 analogues for treatment of type 2 diabetes in adolescents. Monatsschrift Kinderheilkunde 169:3, pages 253-257.
Crossref
Crossref
Ching‐Chi Chi, Chin‐Yu Lee, Chia‐Yu Liu, Shu‐Hui Wang, Felice Tien O’Donnell & Tao‐Hsin Tung. (2020) Effects of antidiabetic drugs on psoriasis: A meta‐analysis. European Journal of Clinical Investigation 51:2.
Crossref
Crossref
Stephen M. Twigg, Mirella M. Daja, Beth A. O’leary & Michael A. Adena. (2016) Once-daily liraglutide (1.2 mg) compared with twice-daily exenatide (10 μg) in the treatment of type 2 diabetes patients: An indirect treatment comparison meta-analysis. Journal of Diabetes 8:6, pages 866-876.
Crossref
Crossref
Julia K. Mader, Lene Jensen, Steen H. Ingwersen, Erik Christiansen, Simon Heller & Thomas R. Pieber. (2016) Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus. Clinical Pharmacokinetics 55:11, pages 1457-1463.
Crossref
Crossref
Chris de Graaf, Dan Donnelly, Denise Wootten, Jesper Lau, Patrick M. Sexton, Laurence J. Miller, Jung-Mo Ahn, Jiayu Liao, Madeleine M. Fletcher, Dehua Yang, Alastair J. H. Brown, Caihong Zhou, Jiejie Deng & Ming-Wei Wang. (2016) Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes. Pharmacological Reviews 68:4, pages 954-1013.
Crossref
Crossref
Caterina Palleria, Christian Leporini, Francesca Maida, Elena Succurro, Giovambattista De Sarro, Franco Arturi & Emilio Russo. (2016) Potential effects of current drug therapies on cognitive impairment in patients with type 2 diabetes. Frontiers in Neuroendocrinology 42, pages 76-92.
Crossref
Crossref
Eugenia Lampropoulou, Anna Lymperopoulou & Aristidis Charonis. (2016) Reduced expression of ERp46 under diabetic conditions in β-cells and the effect of liraglutide. Metabolism 65:1, pages 7-15.
Crossref
Crossref
R. Sekar, K. Singh, A.W.R. Arokiaraj & B.K.C. Chow. 2016.
279
341
.
Marco Zavattaro, Marina Caputo, Maria Teresa Samà, Chiara Mele, Luisa Chasseur, Paolo Marzullo, Loredana Pagano, Maria Grazia Mauri, Maria Chantal Ponziani, Gianluca Aimaretti & Flavia Prodam. (2015) One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study. Endocrine 50:3, pages 620-626.
Crossref
Crossref
Jiaqiang Zhou, Jiahua Wu, Fenping Zheng, Mengshi Jin & Hong Li. (2015)
Glucagon-like peptide-1 analog-mediated protection against cholesterol-induced apoptosis via mammalian target of rapamycin activation in pancreatic
β
TC-6 cells 胰高血糖素样多肽-1类似物激活mTOR通路减轻胆固醇诱导的
β
TC-6细胞凋亡
. Journal of Diabetes 7:2, pages 231-239.
Crossref
Crossref
Takeshi Osonoi, Miyoko Saito, Atsuko Tamasawa, Hidenori Ishida, Daisuke Tsujino, Rimei Nishimura & Kazunori Utsunomiya. (2014) Effect of Hemodialysis on Plasma Glucose Profile and Plasma Level of Liraglutide in Patients with Type 2 Diabetes Mellitus and End-Stage Renal Disease: A Pilot Study. PLoS ONE 9:12, pages e113468.
Crossref
Crossref
Asger Lund, Filip K. Knop & Tina Vilsbøll. (2014) Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities. European Journal of Internal Medicine 25:5, pages 407-414.
Crossref
Crossref
Aljoša Bavec. (2014) (Poly)peptide-based therapy for diabetes mellitus: Insulins versus incretins. Life Sciences 99:1-2, pages 7-13.
Crossref
Crossref
Yoshiaki Tamura, Yoshiyuki Kimbara, Shingo Funatsuki, Suguru Mabuchi, Remi Kodera, Ayako Yoshimoto, Yuko Chiba, Seijiro Mori, Hideki Ito & Atsushi Araki. (2012) A case of insulin antibody-induced glucose instability in an elderly woman with type 2 diabetes on hemodialysis, successfully ameliorated with liraglutide. Diabetology International 4:1, pages 71-75.
Crossref
Crossref
E. J. Verspohl. (2012) Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes. Pharmacological Reviews 64:2, pages 188-237.
Crossref
Crossref
Bo Ahrén. (2011) GLP-1 for type 2 diabetes. Experimental Cell Research 317:9, pages 1239-1245.
Crossref
Crossref